Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunexpress Closes $6M Financing Round led by Debiopharm

Published: Thursday, March 06, 2014
Last Updated: Thursday, March 06, 2014
Bookmark and Share
Funding to advance development of the Immunexpress SeptiCyte® technology.

Immunexpress Group (Immunexpress) and Debiopharm Diagnostics SA (Debiopharm), have announced the securing of six million U.S. dollars from a financing round, led by Debiopharm.

The funding will be used to advance development of the Immunexpress SeptiCyte® technology and bring one of the company’s late-stage sepsis diagnostic products through to market.

Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Debiopharm Diagnostics SA is part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on investment in cutting edge diagnostic companies.

“The early detection of sepsis is critical. This revolutionary technology will utilize the early immune response to sepsis and potentially lead to a more targeted treatment approach for each patient, which may provide better outcomes for the patients who present with this life-threatening condition,” said Thierry Mauvernay, Delegate of the Board of Debiopharm Group.

Mauvernay continued, “Debiopharm and Immunexpress have been collaborating since June 2012 on the development of one of the Immunexpress investigational products for triaging patients in Emergency Rooms. We are impressed by their work and are confident that the future of sepsis management lies in the use of their innovative diagnostic technology.”

“This is an important milestone for Immunexpress and, ultimately, for the health care community worldwide which is in need of new, improved methods to more quickly and accurately identify and diagnose patients suspected of sepsis,” said Dr Roslyn Brandon, President and Chief Executive Officer, Immunexpress.

Dr Brandon continued, “Support and funding from Debiopharm will provide us with the resources necessary to advance and commercialize our proprietary SeptiCyte® technology for critical care patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Debiopharm to Acquire Affinium’s Antibiotic Clinical Assets and Platform
Company acquire clinical and preclinical assets to identify and develop targeted antibiotics.
Wednesday, February 12, 2014
Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™
Diagnoplex secures 1.3 million Swiss francs from financing round.
Friday, June 07, 2013
Debiopharm, Immunexpress and Biocartis Announce Collaboration
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.
Wednesday, December 26, 2012
Augurix Receives the 2011 ‘Debiopharm /Valais Award’
Company receives award for its point-of-care diagnostic test for the early detection of Celiac disease.
Wednesday, November 16, 2011
Debiopharm Group™ Starts Phase I Clinical Trial with Debio 0932
A targeted small molecule inhibitor of heat shock protein 90 for cancer treatment.
Wednesday, April 28, 2010
Debiopharm Group™ and Biocartis embark on a Partnership Aiming at Enhancing Personalized Medicine
- Debiopharm Group™ , a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
Thursday, April 08, 2010
Debiopharm Group™ Grants Licence for Development, Manufacture and Commercialization of Debio 025
The product is currently in phase 2b clinical development for the treatment of hepatitis C.
Wednesday, February 10, 2010
Scientific News
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
£14m EU Project To Aid Meningitis Diagnosis and Cut Antibiotic Use
An international team of doctors are aiming to develop a rapid test to allow medics to quickly identify bacterial infection in children.
Bringing AFM to Medical Diagnostics
Company has announced that its NanoWizard® AFM and ForceRobot® systems are being used in the field of medical diagnostics in the Supersensitive Molecular Layer Laboratory of POSTECH in Korea.
Scientific Gains May Make Electronic Nose the Next Everyday Device
UT Dallas team breathes new life into possibilities by using CMOS integrated circuits technology.
Electronic Sensor Tells Dead Bacteria From Live
The sensor, which measures 'osmoregulation', is a potential future tool for medicine and food safety.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Genome Sequencing Helps Determine End of TB Outbreak
Using genome sequencing, researchers from the University of British Columbia, along with colleagues at the Imperial College in London, now have the ability to determine when a tuberculosis (TB) outbreak is over.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!